Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysis.

Front Immunol · 2025 · PMC12420618 · PMID 40936915

Europe PMC DOI

hedged sentence

0.1430

closest p · 2.9× alpha

0.1430

boldest claim

The sentences

did not reach statistical significancep = 0.143not close (p > 0.1)

The BRR rate in the EGFR-mutated subgroup (36.4%) was numerically lower than that in the wild-type group, although the difference did not reach statistical significance ( p = 0.143; Figure 3B ). 3.2.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.